Dr. Fizazi discusses potential benefit of triplet therapy for metastatic hormone-sensitive prostate cancer

episode

Urology Times Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Resilience Pivot_ The End of Just-in-Time 3 min · 24 Sep 2026 · Conspiracy Theories Exploring The Unseen

Rugby Daily | NZ to scrap Super Rugby teams? James Tracy's *dream* Leinster head coach 12 min · 24 Sep 2026 · OTB Rugby

Hog Heaven, MAGA Hell 52 min · 24 Sep 2026 · I've Had It

KFC and Gen Z, OAPs and ChatGPT & An Email to Jimmy Fallon. 34 min · 24 Sep 2026 · Ray D'Arcy Daily

Bonds, Stocks Drop as Yields Extend Rally 2 min · 24 Sep 2026 · WSJ Minute Briefing

Judge gives press a pass 4 min · 24 Sep 2026 · Wall Street Breakfast

Report any issue

Source

Recorded03 Mar 2022

Publisheraudioboom.com ↗

Handlerec:11143597

Show notes

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial improved overall survival in patients with metastatic hormone-sensitive prostate cancer with triplet therapy. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in